Gimatecan (sigma-tau industrie farmaceutiche riunite/novartis).
Sigma-Tau Industrie Farmaceutiche Riunite SpA and Novartis AG are developing oral gimatecan, a camptothecin derivative, for the potential treatment of tumors, including glioblastoma.
Nitiss
John L
JL
St Jude Children's Research Hospital, Molecular Pharmacology Department, 332 N Lauderdale Street, Memphis, TN 38105, USA. john.nitiss@stjude.org
Nitiss
Karin C
KC
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical / Q000379:methods / Q000639:trends; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism
D000970:Antineoplastic Agents; C433984:ST 1481; D002166:Camptothecin